Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04252066 · ClinicalTrials.gov registry record
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
A clinical trial of Fabry Disease, sponsored by Amicus Therapeutics.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT04252066 is a study of Fabry Disease that is actively recruiting participants, run by Amicus Therapeutics. The registered enrollment target is 20 participants, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04252066, a study of Fabry Disease, is actively recruiting participants, sponsored by Amicus Therapeutics.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
Conditions Studied
Interventions
- DRUG migalastat
Study Locations (1)
Pennsylvania
- Amicus Therapeutics, Inc. Pregnancy Registry - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2030-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04252066
The ClinicalTrials.gov registry entry for NCT04252066 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (96% lower). The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 1 intervention - of which migalastat is the first listed.
NCT04252066 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04252066 about?
NCT04252066 is a clinical study titled "A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding". This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
What is the current status of trial NCT04252066?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-03-18. Estimated completion is 2030-02.
What conditions does trial NCT04252066 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT04252066?
The interventions under investigation include: migalastat (DRUG).
Who is sponsoring clinical trial NCT04252066?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04252066 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
-
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RECRUITING
-
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.